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Growth Factor
Malgorzata Romanowska1,5, Nadya al Yacoub1,5, Henrik Seidel2, Susanne Donandt3, Hannah Gerken3,
Sandra Phillip3, Nathalie Haritonova3, Metin Artuc3, Susann Schweiger3,4, Wolfram Sterry3 and
John Foerster3
Psoriasis is a common skin disease involving keratinocyte proliferation and altered differentiation, as well as
T-cell activation. Here, we show that altered gene transcription in psoriatic skin lesions is highly reproducible
between independent data sets. Analysis of gene expression confirmed dysregulation in all expected functional
categories, such as IFN signaling and keratinocyte differentiation, and allowed molecular fingerprinting of
a previously characterized dendritic cell subset associated with psoriasis tumor necrosis factor alpha (TNF-a)-
and inducible nitric oxide synthase (iNOS)-producing CD11bINT DC (Tip-DC). Unexpectedly, a large group of
dysregulated transcripts was related to fatty acid signaling and adipocyte differentiation, exhibiting a pattern
consistent with the activation of peroxisome proliferator-activated receptord (PPARd). PPARd itself was strongly
induced in psoriasis in vivo. In primary keratinocytes, PPARd was induced by the transcription factor activator
protein 1, in particular by junB, but not by canonical WNT signaling, in contrast to its regulation in colon
carcinoma cells. Activation of PPARd enhanced proliferation of keratinocytes, while this was inhibited by
knockdown of PPARd. Finally, heparin-binding EGF-like growth factor (HB-EGF), known to induce epidermal
hyperplasia and itself overexpressed in psoriasis, was identified as a direct target gene of PPARd. The present
data suggest that activation of PPARd is a major event in psoriasis, contributing to the hyperproliferative
phenotype by induction of HB-EGF.
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INTRODUCTION
Psoriasis is a common inflammatory skin disease involving
altered keratinocyte differentiation, for example (Gandarillas
et al., 1999; Hobbs et al., 2004), accumulation of dendritic
cells (DCs) (Lowes et al., 2005), as well as T-cell activation
(Boyman et al., 2004; Kohlmann et al., 2004). Genetically,
psoriasis exhibits a polygenic as well as heterogeneous
inheritance pattern (reviewed in Rahman and Elder, 2005).
Clinically and histologically, however, the disease is quite
uniform, despite case-to-case variability, suggesting that the
interplay of susceptibility alleles and exogenous factors
terminates in a common set of molecular changes.
Expression profiling has been used in several studies to
characterize transcriptional changes in psoriasis (e.g., Oes-
treicher et al., 2001; Nomura et al., 2003; Zhou et al., 2003;
Kulski et al., 2005; Quekenborn-Trinquet et al., 2005). When
profiling the transcriptome in whole skin samples, a sizable
fraction, if not the majority, of dysregulated transcripts might
be expected to constitute ‘‘noise’’ due to inhomogenous
sampling. Therefore, microarray studies in psoriasis to date
have analyzed lists of transcriptional changes by a candidate
approach, assigning relevance to specific transcripts based
on their involvement in well-established aspects of the
disease, such as keratinocyte differentiation, IFN signaling,
or influx of inflammatory cells. By this approach, however, a
large portion of transcriptional changes may be dismissed
as artefacts, precluding the identification of unrecognized
relevant signaling pathways.
The transcription factor peroxisome proliferator-activated
receptord (PPARd) contributes to the regulation of adipogen-
esis, glucose metabolism, myogenesis, and macrophage
function, and has previously been shown to be upregulated
in psoriasis (Westergaard et al., 2003). This transcription
factor is expressed in basal and suprabasal epidermal kerati-
nocytes (Westergaard et al., 2001), is induced by IFN-g,
stress-activated kinase, or tumor necrosis factor-a (TNFa)
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via activator protein 1 (AP1)-mediated transcription, and
contributes to the so-called ‘‘regenerative skin phenotype’’
characterizing the late phase of wound healing (Tan et al.,
2001; Di-Poi et al., 2003). Furthermore, PPARd regulates
keratinocyte differentiation, blocks apoptosis (reviewed in
Icre et al., 2006), and induces angiogenesis (Piqueras et al.,
2006), adding to an activity profile highly consistent with a
role in psoriasis.
To be activated, all PPAR isoforms require binding of fatty
acid ligands shuttled by fatty acid-binding proteins. One of
these, psoriasis-associated fatty acid-binding protein
(¼ FABP5), specifically interacts with PPARd (Tan et al.,
2002), is upregulated in psoriasis (Madsen et al., 1992), and is
enriched in the highly proliferative transit amplifying
keratinocyte subset (O’Shaughnessy et al., 2000). Moreover,
the retinoic acid shuttle cellular retoinic acid-binding protein
II is overexpressed in psoriasis (Siegenthaler et al., 1992),
possibly activating PPARd, since retinoic acid itself is a high-
affinity PPARd ligand (Shaw et al., 2003). Furthermore, all
PPAR isoforms require heteromerization with retinoid acid
X-receptora for full activity (Kojo et al., 2003; Tan et al., 2005).
The precise effects of PPARd on PPARa/g activity, and vice
versa, have not been precisely defined in vivo to date
because of superimposed ligand and co-regulator effects; but
the outcome of PPARd activation is clearly distinct from that
of PPARa/g activation. Specifically, PPARdmay act as a direct
antagonist to PPARg (Zuo et al., 2006), or be effected in
opposite fashion to PPARg by the same ligand (Jarvis et al.,
2005). Furthermore, unliganded PPARd itself can act as a
dominant negative to the ligand-containing isoform (Lee
et al., 2006). In light of these data, it is not surprising that
activation of PPARg has an inhibitory effect on psoriasis,
whereas this is not the case with PPARd (Kuenzli and Saurat,
2003; Malhotra et al., 2005).
Here, we show that the vast majority of all transcriptional
changes in psoriatic skin lesions are highly reproducible
across two independent studies. While all expected changes,
such as DC- and IFN-related gene upregulation, were
observed, a large group of altered genes was involved in
fatty acid signaling, with a profile suggestive of PPARd
activation. Heparin-binding EGF-like growth factor (HB-
EGF), an established inducer of epidermal hyperplasia
(Kimura et al., 2005), was identified as a direct target gene
of PPARd. Our data suggest that activation of PPARd is a key
element in psoriasis and identify deranged intermediary
metabolism as a hitherto unrecognized feature of the disease.
RESULTS
Transcriptional dysregulation in psoriasis is highly reproducible
Expression profiling from lesional versus non-lesional psori-
atic skin was performed in five patients with active disease, as
detailed in Materials and Methods. Several types of analyses
were carried out to rule out significant distortions and to
confirm that non-lesional and lesional samples are clearly
distinguishable in their expression profiles, that is that
microarray analysis predicts disease status with certainty
(Figure S1). Approximately, 3.6% of the 12,600 transcripts
were up- and 2.1% downregulated by twofold or more when
applying a threshold of Po0.05 in a Welsh-weighted t-test
(see Supplementary Material ‘‘Charite´ all transcripts’’). To
estimate the extent of artificial alterations due to inhomo-
genous sampling, we quantified the changes reported in a
previous study employing a comparable experimental plat-
form (Affimetrix U95 microarray; Zhou et al., 2003). Those
data include 326 transcripts upregulated by twofold or more
in lesional skin. Applying the same threshold to the subset of
validated translated genes, we were in fact able to confirm
80% of all tested transcripts (Table 1). When lowering the
cutoff to X1.5-fold upregulation, almost 90% of upregulated
transcripts were observed in both data sets. Only four
transcripts, not confirmed in the current data set, were
significantly upregulated in the previous data set (X3-fold):
IL-7 receptor, CLUAL protein, RASGRP2, RGS1. Three of
these transcripts (IL-7 receptor, RASGRP2, RGS1) are T-cell
associated, and two (RASGRP2 and RGS1) upregulated in
CD4þ T cells, suggesting that the discrepancy may be in fact
be explained by uneven sampling of CD4þ T cells known to
localize preferentially subepidermally in psoriatic lesions.
Likewise, approximately, 70% of transcripts reported to be
downregulated by Zhou et al. (2003) were also downregulated
in the current data set. Only 10 genes significantly down-
regulated (X2.5-fold) could not be confirmed. Thus, inde-
pendent expression profiles comprising data from 17 patients
exhibit an unexpected level of concordance. Other available
microarray data sets (Oestreicher et al., 2001; Itoh et al.,
2005; Quekenborn-Trinquet et al., 2005) were not included in
the present meta-analysis because of differences in experi-
mental procedure, but collectively confirm the notion that
transcriptional changes in psoriatic lesions are highly repro-
ducible despite sampling complex cell-type mixtures. Thus,
the majority of these transcripts do not represent random
noise, but are probably related to disease pathogenesis, and
must consequently be considered in data analysis.
Table 1. Concordance of transcriptional regulation in
lesional psoriatic skin in two independent data sets1
Upregulated Downregulated
n % n %
Translated mRNAs2 187 170
Not tested3 50 74
Confirmed of tested4 123 89.7 67 69.8
Significantly discrepant5 4 2.9 10 10.4
1As reported in http://hg.wustl.edu/bowcock/papers/hg2003/zhou/I_U_
up_2.0.xls.
2ESTs, hypothetical ORFs, and multiply hybridized mRNAs were excluded
from analysis.
3Transcript not present on microarray or signal below threshold.
4CutoffX1.5-fold for upregulated and X1.2-fold for downregulated
transcripts (as used by Zhou et al., 2003). When cutoff X2.0-fold for
upregulated andX1.5-fold for downregulated transcripts were applied (as
used by Zhou et al., 2003), the concordance was 80.3%. Specific fold
changes and P-values for all genes are detailed in the Supplementary
Material (‘‘Charite´ all transcripts’’).
5Transcripts reported to be upregulated X3.0-fold or downregulated
X2.5-fold by Zhou et al. (2003) but not confirmed in the current data set.
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Psoriasis-specific gene regulation
In addition to identifying genes exhibiting consistent
changes in independent data sets, we sought to uncover
changes specific to psoriasis. To this end, we performed
expression profiling of transcriptional changes in lesional
versus non-lesional skin from atopic dermatitis and contact
allergy, processing all samples identical to the psoriasis
samples. We then filtered the entire data set to include
genes regulated either exclusively in psoriasis or at least
twofold less in the latter diseases. These genes (shown in
Table 2) define a disease-specific pattern of gene dysregula-
tion. Unexpectedly, the largest group of genes was related to
fatty acid signaling. Thus, highly reproducible and disease-
specific expression profiling suggests that aberrant fatty
acid signaling is a central feature of psoriatic pathogenesis
(see below).
DC-related genes
As expected, numerous type 1 IFN-induced genes were found
upregulated in lesional psoriasis (Table 2, second group).
While the best characterized source of IFN-a is the
plasmacytoid DC subset (Gary-Gouy et al., 2002), a myeloid
CD11cþ DC subset was recently characterized in psoriatic
lesional skin (Lowes et al., 2005). Therefore, we screened the
present microarray data for transcripts allowing indirect
fingerprinting of DC subsets. This analysis, summarized in
Table 3, revealed upregulation of transcripts highly indicative
of the myeloid CD14 CD1þ DC subset as defined in Ahn
et al. (2002) and consistent with the DC phenotype reported
by Lowes et al. (2005), suggesting that this myeloid DC
subset, and not plasmacytoid DCs, may in fact be the primary
source of type 1 IFN secretion in psoriatic epidermis.
Furthermore, the upregulation of kynuroninase and indolea-
mine dioxygenase points to a potential mechanism for the
relative scarcity of CD4þ T cells in psoriatic epidermis, as
those genes are involved in DC-mediated inhibition of CD4þ
T cells (Marteau et al., 2005). Finally, the strongly upregu-
lated chemokine CCL20 has been identified as critical
chemoattractant for CD11cþ DCs into the skin (Le Borgne
et al., 2006). Thus, the upregulated transcripts listed in
Table 3, which are largely confirmed in independent studies,
as a group defines a molecular profile of the expanded
mature myeloid DC subset in psoriasis.
Dysregulation of genes related to fatty acid signaling in psoriasis
Transcripts congruently regulated in two independent data
sets were grouped into functional categories. Although this
procedure is somewhat arbitrary, it clearly showed that
a large group of dysregulated genes were related to fatty
acid signaling (Figure 1). Several of these were related to
adipogenesis, fatty acid shuttling, the peroxisomal oxidative
response, and sebocyte regulation, and are detailed in
Table 4. All these processes are regulated by PPARd, which
was itself one of the most strongly upregulated transcripts
(10.1-fold; P¼ 0.017), confirming previous reports (Wester-
gaard et al., 2003). Additional transcripts dysregulated in
both data sets were associated with other processes regulated
by PPARd, that is myogenesis and glucose turnover (listed in
the Supplementary Material ‘‘gene categories’’). Taken
together, a large fraction of dysregulated transcripts in
lesional psoriasis strongly suggests activation of PPARd,
which, in addition, is also a key regulator of keratinocyte
differentiation and apoptosis (Tan et al., 2003, 2004;
Schmuth et al., 2004).
Expression of two PPARd isoforms in vitro
Previously, a mixed nuclear and cytosolic expression of
PPARd has been shown in psoriatic epidermis on the protein
level (Westergaard et al., 2003). To study whether over-
expression of PPARd is maintained in vitro, and to study the
subcellular distribution of PPARd in vitro, we cultivated
primary keratinocytes and prepared nuclear and cytosolic
extracts. As shown in Figure 2a, PPARd was expressed at
widely varying levels in keratinocytes, which expanded from
lesional or non-lesional psoriatic skin as well as from control
skin. Thus, the established overexpression of PPARd in
lesional psoriasis does not represent a cell-autonomous
phenotype of keratinocytes from psoriatic individuals. Inter-
estingly, two isoforms were detected using an N-terminally
directed antibody, migrating approximately 2–3 kDa apart at
the expected size of 55 kDa. The shorter of these isoforms
was clearly predominant in the nucleus. HaCaT keratinocytes
only exhibited the smaller isoform both in cytosol and the
nucleus (blot shown on right). The specificity of both bands
was confirmed using peptide competition (Figure 2b). Next,
we activated PPARd by addition of the synthetic ligand
L-165041 in primary keratinocytes from three donors. As
shown in Figure 2c, while PPARd was again found to range
widely, addition of synthetic ligand did not result in
consistent translocation to the nucleus. Whether the two
isoforms represent differentially phosphorylated isoforms,
analogous to PPARa/g, is currently under investigation. Taken
together, these data show that, as yet uncharacterized, PPARd
isoforms are enriched in different subcellular compartments
and that the subcellular localization of PPARd is independent
of its activation status.
Localization of NF-jB is independent of PPARd
Since p65/RelA and PPARd have previously been reported to
interact in a ligand-dependent manner (Westergaard et al.,
2003), we examined localization of p65 at steady-state
conditions, as well as upon activation of PPARd. As shown in
Figure 2d, p65/RelA exhibited predominantly cytosolic
localization in primary keratinocytes. Activation of PPARd
did not induce nuclear accumulation of p65/RelA. We
conclude that in adult epidermal keratinocytes NF-kB
translocation is not regulated by PPARd ligation. Therefore,
heterodimerization of p65/RelA and PPARd is unlikely to
contribute to PPARd activity in the epidermis.
PPARd is regulated through AP1 activation in keratinocytes
The transcriptional regulation of PPARd is complex; several
trans-acting factors have been described to date. In murine
keratinocytes, a major transcriptional activation has been
shown to initiated by IFN-g, stress-activated kinase, and
TNFa, all of these pathways being integrated by an AP1 site
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Table 2. Genes-regulated disease – specifically in psoriasis1
Fold change
Symbol PS AD CA P-value2
Adipogenesis, fatty acid signaling
PPARd PPARB 10.1 3.9 1.7 0.017
Lipocalin 2 LCN2 7.7 1.9 1.3 0.010
Fatty acid-binding protein 5 FABP5 5.8 2.9 1.8 0.000
Cellular retinoic acid-binding protein II CRABPII 5.0 1.6 1.6 0.003
12R-Lipoxygenase ALOX12B 3.7 2.0 1.5 0.002
Thyroxine deiodinase II, skeletal muscle DIO2 3.0 1.1 1.3 0.012
Retinoic acid-receptor responder 1 RARRES1 2.3 1.3 1.4 0.001
Carnitine acetyltransferase CRAT 5.4 2.0 2.7 0.014
Protein phosphatase 1, regulatory subunit 3C PPP1R3C 2.9 1.4 2.0 0.007
Protein kinase C-like 1 (PRK1) PRKCL1 2.1 1.1 1.1 0.006
Interferon induced
Interferon-stimulated protein, 15 kDa ISG15 7.2 1.6 2.6 0.000
20,50-Oligoadenylate synthetase 1 OAS1 6.6 2.3 2.6 0.000
MX 1 (IFN-inducible p78) MX1 5.9 1.6 2.5 0.001
IFNa-inducible protein (IFI-6-16) G1P3 4.1 2.0 1.1 0.003
DC related
CD24 antigen CD24 5.0 1.4 2.6 0.000
Cystatin A (stefin A) CSTA 4.3 1.4 2.1 0.001
ADAM-like (decysin 1) ADAMDEC1 4.0 1.1 1.4 0.000
LAMP3 (DCLAMP) LAMP3 3.8 1.5 2.1 0.000
Chemokine (C–C motif) ligand 20 CCL20 3.3 1.1 1.2 0.004
Mitosis/cell cycle
Ki67 MKI67 4.4 1.5 2.0 0.001
M-phase phosphoprotein 6 MPHOSPH6 4.1 1.8 1.7 0.004
KIAA0101 gene product KIAA0101 3.8 1.6 2.0 0.000
Mitogen-activated protein kinase 6 MAPK6 3.8 1.4 1.7 0.006
DKFZP434C212 protein GAPVD1 3.4 1.1 1.8 0.010
MAD2 mitotic arrest deficient-like 1 MAD2L1 2.7 1.3 1.3 0.006
HRAS-like suppressor 3 HRASLS3 4.2 1.0 1.4 0.009
Keratinocyte differentiation/desquamation
Kallikrein 6 (neurosin) KLK6 10.5 1.6 3.4 0.002
Kallikrein 13 KLK13 6.2 1.0 1.2 0.000
kallikrein 10 KLK10 4.6 2.0 1.6 0.006
Small proline-rich protein 2C SPRR2C 24.7 1.8 2.2 0.000
Transglutaminase 1 TGM1 4.4 1.9 1.8 0.000
Paired-like homeodomain transcription factor 1 PITX1 5.1 2.8 1.2 0.007
Adhesion
S100 calcium-binding protein A2 S100A2 4.3 1.9 1.6 0.000
Olfactomedin 1 OLFM1 3.8 1.7 1.6 0.000
Collagen XIVa 1 (undulin) COL14A1 2.6 1.2 1.0 0.003
Table 2 is continued on the following page
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in the PPARd promoter (Tan et al., 2004). To assess the
contribution of this cis-acting element, we blocked expres-
sion of two AP1 subunits active in adult epidermis, c-jun and
junB, by RNA interference in HaCaT keratinocytes. As shown
in Figure 3a, knockdown of junB greatly reduced steady-state
PPARd expression, whereas c-jun knockdown had only a
minor effect. By contrast, knockdown of b-catenin, which has
been reported to strongly regulate PPARd expression in colon
carcinoma cells (He et al., 1999), had a negligible effect on
PPARd expression (Figure 3b), both in normal and in calcium-
free medium. This was not due to incomplete cell infection,
as shown in Figure 3c. Thus, PPARd expression in human
keratinocytes is primarily regulated via AP1 activation, speci-
fically by junB, whereas canonical Wnt signaling has no
effect.
PPARd enhances proliferation in keratinocytes
Keratinocyte proliferation is greatly increased in psoriasis.
Since PPARd can either block or enhance cellular prolifera-
tion, depending on cellular context, we examined the effect
of PPARd on proliferation in human keratinocytes. To this
end, HaCaT keratinocytes, which are fast cycling under
steady-state conditions, were infected with a lentivirus
containing an RNAi sequence recognizing PPARd or control
lentivirus. As shown in Figure 4a, the infection ratio for both
vectors, quantified by FACS analysis of the green fluorescent
protein reporter was approximately 94% for both vectors.
However, 13 days after infection, the percentage of green
fluorescent protein-positive cells had decreased significantly
only after infection with PPARdRNAi, but not after control
virus, indicating a proliferative disadvantage in the absence
of PPARd. In a complementary approach, adult primary
epidermal keratinocytes, which are proliferating much slower
than HaCaT cells, were exposed to the PPARd-specific
ligands L-165041 or GW-501516. As shown in Figure 4b
and c, stimulation with either ligand caused a highly
significant increase in cell number in keratinocytes expanded
from three independent donors. These data indicate that
PPARd augments, rather than inhibits, keratinocytes prolife-
ration, suggesting that this effect may contribute to keratino-
cyte hyperproliferation in psoriasis.
Heparin-binding EGF-like growth factor is a target of PPARd
We next sought to identify target genes activated by PPARd
activation involved in enhanced proliferation. To this end,
primary keratinocytes from four independent donors were
Table 2. continued
Fold change
Symbol PS AD CA P-value2
Apoptosis
H2A histone family, X H2AFX 4.5 1.4 1.4 0.009
Flap structure-specific endonuclease 1 FEN1 3.5 1.4 1.9 0.005
Wound response
Secretory leukocyte protease inhibitor SLPI 3.1 1.1 1.3 0.012
TGFb receptor III=betaglycan TGFBR3 3.5 1.8 1.7 0.012
Miscellaneous (putative role indicated in parentheses)
IL-1b IL1B 5.9 1.6 1.8 0.013
Uridine phosphorylase (TNF induced) UP 7.1 1.8 1.8 0.001
WNT 5a (differentiation) WNT5A 4.5 2.2 2.0 0.000
Inhibitor of DNA binding 1 (angiogenesis) ID1 3.0 1.6 1.2 0.014
LIV-1 (estrogen regulated) LIV-1 2.7 1.3 1.3 0.011
Transcobalamin I (neutrophils) TCN1 16.9 2.1 1.4 0.002
LIM domain protein (cytoskeleton) RIL 3.0 1.3 1.5 0.001
Chemokine (C–C motif) ligand 27 (Th 2 recruitment) CCL27 7.1 2.1 1.3 0.000
Solute carrier family 1 member 6 (peripheral nerves) SLC1A6 2.6 1.4 1.1 0.010
MGC24447 (unknown function) C14orf147 3.1 1.1 1.3 0.001
IFN, interferon; PPARd, peroxisome proliferator-activated receptord; TGFb, transforming growth factor; TNF, tumor necrosis factor.
1Genes specifically up- or downregulated in psoriasis skin lesions (n=5), but not in lesional atopic dermatitis (AD, n=4) or experimentally induced contact
allergy (CA, n=4). The genes listed in the table satisfied the following criteria: (1) fold change42.5 and P-value o0.02 for psoriasis; (2) relative change at
least two-fold higher in psoriasis; (3) P-values 40.01 in AD and CA. Sample processing, data acquisition, and analysis was performed as specified in
Materials and Methods.
2Only P-values pertaining to psoriasis are shown since transcripts with P-valueso0.01 in AD or CA were considered non-specific for psoriasis and omitted
by the filter settings.
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grown in the presence of L-165041, or vehicle, for 48 hours.
Total gene expression was then analyzed using the PIQUOR
SkinPatho array, which contains approximately 1,100 tran-
scripts relevant to epidermal biology. The magnitude of gene
induction by PPARd has been found to lie in the range of
1.5–3-fold in previous microarray studies (Tan et al., 2001;
Tanaka et al., 2003; Tachibana et al., 2005). Since this
moderate induction is close to the background level, we
applied a threshold for a minimum fold change of greater
than three standard deviations of the mean fold change
observed across all genes (illustrated in Figure 5a). Although
this conservative approach reduced sensitivity, thus prevent-
ing detection of further potential target genes, it largely
eliminates identification of false positives. Table 5 sum-
marizes the observed changes. Several of the listed genes
pertaining to fatty acid metabolism have previously been
identified as targets in other cell types (Tanaka et al., 2003;
Tachibana et al., 2005), thus confirming the present data.
One gene, HB-EGF was of particular interest because it is also
upregulated 3.6-fold in vivo in lesional psoriasis (Table 5) and
because it is known to enhance keratinocyte proliferation.
We, therefore, confirmed the observed upregulation of
HB-EGF by quantitative real-time PCR. As a positive control,
we used CIDE-A, an proapoptotic gene previously shown to
be indirectly downregulated by PPARd (Tan et al., 2001).
Expression of PPARd itself was used as negative control. As
shown in Figure 5b, both HB-EGF and CIDE-A were
moderately, but statistically significant induced by PPARd
activation in four independent patients, whereas expression
of PPARd itself did not change, in confirmation of the
microarray data. On the protein level, HB-EGF expression
was increased on activation of PPARd (Figure 5c, left) and
decreased after lentivirus-mediated knockdown of PPARd in
primary keratinocytes (Figure 5c, right). Finally, we addressed
whether HB-EGF is directly or indirectly induced by PPARd.
To this end, primary keratinocytes were incubated in the
absence, or presence, of L-165041, with or without cyclo-
heximide. Subsequently, HB-EGF expression was determined
by reverse transcription-PCR (RT-PCR). ACADVL, an estab-
lished PPARd target gene was amplified as positive control.
CIDE-A, previously shown to be indirectly induced by PPARd
(Tan et al., 2001), was used as a negative control. As shown
in Figure 5d, induction of CIDE-A by PPARd activation could
be suppressed, whereas this was not the case for ACADVL
and HB-EGF. Thus, HB-EGF is a direct target gene of PPARd.
DISCUSSION
Several independent lines of evidence implicate PPARd in
psoriasis. PPARd is highly, and specifically, upregulated in
psoriasis. The activity profile of this nuclear hormone
receptor includes antiapoptotic and proangiogeneic effects,
Table 3. Upregulation of dendritic cell-related
transcripts in psoriatic lesional skin
Gene name Symbol
P-
value
Fold
change
Genes specific for CD1+CD14 subset1
Cystatin A CSTA 0.001 4.3
Lysosomal-associated
membrane protein 3
LAMP3 0.000 3.8
Act. RNA pol II transcription
cofactor 4
PC4 0.014 3.7
B-cell linker BLNK2 0.000 2.9
Matrix metalloproteinase 12 MMP12 0.114 2.6
Annexin A2 ANXA22 0.320 2.1
Isocitrate dehydrogenase 3 IDH3A2 0.000 2.0
DC associated 3
Indoleamine dioxygenase INDO2 0.011 2.1
Kynureninase KYNU 0.059 3.4
Inducible NO synthase NOS2a 0.021 3.3
CD47 antigen CD47 0.004 3.3
C-type lectin 12 =Dectin 1 CLECSF12 0.175 2.5
Regulator of G-protein
signaling 20
RGS12 0.000 4.3
Fc-g receptor IIIb FCGR3B 0.067 2.4
CD24 antigen CD24 0.000 5.0
RNA helicase RIG-I 0.024 2.2
decysin 1 ADAMDEC1 0.000 4.0
CCL20=MIP3a4 CCL20 0.003 3.3
DC, dendritic cells.
1As defined by Ahn et al. (2002).
2Not reported to be upregulated in psoriasis to date: PC4, BLNK, ANXA2,
IDH3A, and INDO.
3Independently confirmed in Bowcock et al. (2001) and Zhou et al.
(2003).
4Confirmed in Nomura et al. (2003).
Miscellaneous
Stress/ROS
Myogenesis/
cytoskeleton
Membrane
trafficking
Apoptosis
TNF-induced
Neuronal
Gland-associated
Wound response
T cells
Migration
Adipogenesis
Wnt-related
Angiogenesis
DCs
Adhesion
IFN-dependent
Mitosis/cell cycle
Fatty acid signalling
Keratinocyte
differentiation
Desquamation/
cornification
Figure 1. Functional distribution of transcripts with altered expression in
lesional psoriatic skin in two independent data sets. (Shown are current data
and Zhou et al., 2003; total number of genes classified: n¼ 175). Genes with
known roles in multiple categories were simultaneously assigned to all
relevant categories. For an annotated list of all changes, see Supplementary
Material ‘‘Charite´-gene categories’’. ‘‘Miscellaneous’’ contains the following
categories: IL-1 related; stem cell differentiation associated; glucose
metabolism; neutrophil related.
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Table 4. Genes dysregulated in psoriatic lesions related to fatty acid signaling1
Gene name
FC (Zhou
et al.,
2003)
FC
(this
report)
Putative functional
relationship to PPARd
Adipo-
genesis
PPAR
ligand
related
PPARa/c
modu-
lation
Oxidative
response
Per-
oxisome
Sebaceous
glands
Upregulated
Lipocalin 2 9.9 7.7 PKB/Akt target in adipocyte
differentiation (Baudry et al., 2006)
x
FABP5 5.3 5.8 Ligand shuttle, psoriasis specific
(see Introduction)
x
ALDH1A3 3.4 4.8 Retinoic acid synthesis x
t-PA (PLAT) 2.3 3.9 Adipocyte differentiation (Seki et al., 2001)
and angiogenesis (Merchan et al., 2003)
x
HIF1A 2.4 3.8 Induces VEGF and ABCA, oxidative
stress, inhibits PPARa, PPARg2
x x
ALOX12B 2.7 3.7 Psoriasis-specific and ligand
synthesis (see Discussion)
x
SOD2 3.2 3.1 Adipocyte differentiation inhibitor
(Lechpammer et al., 2005), PPARd target
x x
MAP17
(DD96)
3.1 2.9 Increases HDL, binds PDZK1
(Silver, 2003)
SLC6A14 7.4 2.2 Associated with obesity (Suviolahti,
2003)
SLC16A1 2.1 2.1 Short-chain FA transport (Gill et al., 2005),
muscle mitochondra (Butz et al., 2004)
HIP2
(E2-25 K)
2.6 1.7 LDL-induced, antiapoptotic, ubiquitin
conjugase
APOL1* 2.5 1.5 Endothelial-cell specific, HDL associated
(Monajemi et al., 2001)
Downregulated
FMO5 2.0 1.6 Detoxification, progesteron induced
HELO1* 2.5 1.7 Lipogenesis, polyunsaturated C16-C20
synthesis (Leonard, 2000)
x x
ALOX15B* 5.0 1.9 Activator of PPARa g x
PXF (PEX19) 2.0 1.9 Peroxisome membrane trafficking
(Hoepfner et al., 2005)
x
GATA3 2.5 1.9 Adipocyte differentiation
suppressor (Tong, 2005)
x
HIBADH 2.5 2.1 Fibroblast differentiation toward
lipocytes (Kedishvili et al., 1994)
x
ALDH3A2 2.0 2.2 FA aldehyde oxidation,
12R-LOX related, lipoxin synthesis
x x
ABCA8 2.0 2.2 Cholesterol and phospholipid
shuttle to apolipoproteins
x x
PDZK1* 10.0 2.3 Binds MAP17
FASN* 3.3 2.4 Stratum granulosum (Uchiyama
et al., 2000), associated with glands
ID4 3.3 2.5 Adipocyte differentiation associated
(Chen et al., 1999)
x
CYP1B1 2.0 2.6 Adipocyte differentiation, induced by
PPARa,g; oxidative stress (Cho, 2005)
x x x
transferrin* 2.5 3.0 Adipocyte differentiation enhancement
(Hemmrich et al., 2005)
x
Table 4 is continued on the following page
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as well as regulation on keratinocyte differentiation. PPARd is
activated by TNFa, a central mediator of the inflammatory
response in psoriasis. Its interaction partners FABP5 and
cellular retinoic acid-binding protein II are upregulated in
psoriasis (Table 2). To this list, we here add (1) that a large
group of dysregulated genes in psoriasis lesions in vivo are
related to PPARd function; (2) that PPARd enhances
keratinocyte proliferation; (3) that it directly induces HB-
EGF. The role of PPARd on proliferation is, in fact, highly
controversial and other recent papers report a growth-
inhibitory effect (Burdick et al., 2007). However, using
primary adult epidermal human keratinocytes, we observe a
growth-stimulatory role using two different PPARd ligands.
Since the stimulatory time period used was 7 days, the obser-
ved increase in cell number is highly unlikely to result
exclusively from inhibited apoptosis. Therefore, it appears
that PPARd activation in human keratinocytes indeed
enhances proliferation. HB-EGF represents a highly relevant
target, since it drives keratinocyte proliferation, regulates
wound healing, and induces epidermal hyperplasia, thus
replicating important elements of the psoriatic phenotype
in vivo (Zheng et al., 2003; Kimura et al., 2005; Shirakata
et al., 2005). Moreover, we define two regulatory aspects of
PPARd activity in keratinocytes: its expression is independent
of canonical Wnt signaling and its localization and activity is
independent of p65/RelA.
A discussion of all disease-specific changes in psoriasis
(Table 3) is beyond the scope of the current report. However,
the genes involved in fatty acid signaling as a group (Table 3,
top section) constitute a disease-specific determinant of
PPARd activity in psoriasis. Thus, FABP5 and cellular retoinic
acid-binding protein II regulate PPARd activity by fatty acid
ligands. Moreover, FABP5 enhances keratinocyte motility in
wounds (Kusakari et al., 2006). 12R-Lipoxygenase catalyzes
the formation of 12R-HETE, which specifically accumu-
lates in psoriasis and has been shown to activate PPARd
(Westergaard et al., 2003). Lipocalin 2 is junB induced,
modulates adipocyte differentiation, and wound healing
(Florin et al., 2006). Dio2 regulates brown fatty tissue
homeostasis (Christoffolete et al., 2004). RARRES1, down-
regulated in psoriasis (Table 3), blocks keratinocyte prolifera-
tion (DiSepio et al., 1998). Carnitine acyltransferase regulates
fatty acid b-oxidation. PPP1R3C (PTG) regulates glycogen
metabolism (Printen et al., 1997). The serine/threonine kinase
PRK1, found to be downregulated, inhibits phosphorylation
of PKB/AKT by lipids (Wick et al., 2000; Lim et al., 2005),
which is activated by PPARd. Taken together, these genes
underscore the complex regulation of adipogenesis, lipid,
and glycogen metabolism exerted by PPARd, and reinforce
the concept of psoriasis as a dysregulated wound response
program.
The unexpectedly large group of dysregulated genes invol-
ved in fatty acid metabolism positions intermediary metabo-
lism as a central aspect of the disease, connected to, but
distinct from its inflammatory nature. Thus, increased body
mass index is an independent risk factor for psoriasis (Naldi
et al., 2005) and may have an effect on disease severity
(Marino et al., 2004), as well as TNFa-related inflammatory
activity (Hamminga et al., 2006). Since the prevalence of
metabolic syndrome is increased in psoriasis (Sommer et al.,
2006), a combination of insulin resistance, obesity, or
chronic inflammation may trigger the expression of PPARd,
which in turn contributes to a non-terminated regenerative
skin phenotype. This disease mechanism would be expected
Table 4. continued
Gene name
FC (Zhou
et al.,
2003)
FC
(this
report)
Putative functional
relationship to PPARd
Adipo-
genesis
PPAR
ligand
related
PPARa/c
modu-
lation
Oxidative
response
Per-
oxisome
Sebaceous
glands
EPHX1 2.0 3.2 Activates PPARa, peroxisomal and
microsomal location
x
APOE 3.3 3.6 Sebaceous glands x
APOD 2.5 3.9 Sebaceous glands x
RBP4 3.3 5.2 Shuttles retinoic acid; mediates insulin
resistance (Yang et al., 2005)
x
CRAT 2.5 5.4 Peroxisomal and mitochondrial b-oxidation x
FABP7 5.0 6.6 Induced by PPARd in stellate cells
(Hellemans et al., 2003)
FADS1 10.0 7.7 Induced by SREB1 and PPARa
(Matsuzaka et al., 2002)
x
APOC1 2.0 8.1 Apocrine and sebaceous glands x
FADS2* 5.0 13.8 Sebaceous gland-specific (Ge et al., 2003) x
HDL, high-density lipoprotein; LDL, low-density lipoprotein; PPARd, peroxisome proliferator-activated receptord; VEGF, vascular endothelial growth factor.
1Genes congruently regulated in Zhou et al. (2003) and the current data set with a documented function in fatty acid signaling. (*) marks genes with a P-value
of 0.05–0.2 (Welsh-weighted t-test) in the Charite´ data set (see Supplementary Material ‘‘Charite´ all transcripts’’). All other genes have Po0.05 in both data
sets.
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to be aggravated by acute inflammation, or stress via the
induction of PPARd by TNFa and stress-activated kinase (Tan
et al., 2001). Clinically, these factors are precisely the most
potent triggers of disease flares. Thus, activation of PPARd in
psoriasis offers a pathogenetic concept unifying various
clinical aspects as well as transcriptional changes in psoriasis.
Therapeutically, since caloric restriction can decrease the
expression level of PPAR isoforms (Masternak et al., 2005),
trials to this end appear warranted to explore the efficacy of
caloric restriction as a treatment option in appropriately
selected psoriasis patients. Conversely, currently on-going
trials employing PPARd agonists for the treatment of
metabolic syndrome and obesity should be carefully scruti-
nized for increased incidence of psoriasis.
Mechanistically, PPARd may act as an antagonist to other
nuclear hormone receptor heterodimers. Thus, the RXR/RAR
heterodimer activates, rather than inhibits apoptosis (Chiba
et al., 1997; Monczak et al., 1997). Another competitive
antagonism may be exerted toward PPARg, since activation
of this isoform directly inhibits STAT3 (Wang et al., 2004)
which, when overexpressed, causes a psoriasis-like pheno-
type in vivo (Sano et al., 2005). Furthermore, the antiapop-
totic activity of PPARd may be most pronounced in the
context of type 1 IFN activity, since PPARd is expressed in
DCs (Jakobsen et al., 2006). In fact, we have observed that
PPARd can be induced by IFN-a (N.a.Y and J.F., paper in
preparation), adding yet further support for a role of PPARd
in psoriasis.
The upregulation and activity of PPARd in lesional
psoriasis suggests how the psoriasis-like phenotype in K14-
vascular endothelial growth factor transgenic mice relates to
the human disease, since vascular endothelial growth factor
is a target gene of PPARd (Xia et al., 2003; Sano et al., 2005).
It is also intriguing that, in contrast to human skin, PPARd
is not expressed in adult interfollicular mouse epidermis,
perhaps explaining why psoriasis form dermatitis does not
occur spontaneously in mice. Finally, it should be pointed
out that the PPARd gene is located 4.2 Mb telomeric of the
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Figure 2. Expression of PPARd and p65/RelA in primary adult keratinocytes. (a) Western blot of nuclear and cytosolic fractions from keratinocytes expanded
from non-lesional, or lesional skin, as well as from healthy control skin, as indicated. Twenty micrograms of nuclear and cytosolic fractions were loaded per
lane. PonceauS staining is shown on the bottom as control for even loading. (b) Cytosolic and nuclear fractions of primary keratinocytes from healthy control
skin were prepared and processed exactly as in panel (a), except that anti-PPARd was pre-incubated with 10mg/ml of antigenic peptide (þ peptide) for
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fractions from keratinocytes from three control individuals stimulated with the PPARd-specific ligand L-165041 (LD) or vehicle (con) for 48 hours. Nuclear
extract from HaCaT keratinocytes was included as positive control (rightmost lane). (d) The blot shown in b was re-probed using p65/RelA antibody.
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putative PSORS1 locus at HLA-C on chromosome 6p21.2.
Since earlier genome-wide scans were performed using
microsatellites located actually closer to the PPARd locus
than to HLA-C and yielding a positive signal (Nair et al.,
1997; Trembath et al., 1997; Enlund et al., 1999), PPARd
formally constitutes a candidate susceptibility gene for the
disease.
MATERIALS AND METHODS
Patients
All work with patient materials presented in the current report was
carried out in accordance with the Declaration of Helsinki
Principles. All patients undergoing biopsy gave prior written consent.
Psoriasis and atopic dermatitis patients sampled for expression
profiling were undergoing in-patient treatment for active disease at
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or presence of siRNA specific for junB or c-Jun, as indicated. Forty-eight hours after transfection, RNA was analyzed by RT-PCR (top panel), and protein by
Western blot (bottom) for the expression of PPARd. (b) HaCaT cells grown under standard conditions or in calcium-free medium were infected with empty
control lentivirus (pLL3.7) or lentivirus harboring a b-catenin-specific siRNA sequence, as indicated in the figure. Forty-eight hours after infection, RNA
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the time of biopsy. Contact allergy was elicited by standard patch
testing for 72 hours on the back.
Expression profiling
Full-thickness lesional and non-lesional 5-mm punch biopsies were
snap-frozen in liquid nitrogen. RNA was purified using the RNeasy
kit (Qiagen, Hilden, Germany). Reverse transcription, second-strand
synthesis, cRNA labeling, and hybridization to the Affimetrix U95A
array was performed according to Mishra et al. (2002). Microarray
processing is detailed in the supplement (legend to Figure S1).
Cell culture
Expansion of adult epidermal keratinocytes on feeder layer was
performed modified according to Rheinwald and Green (1975). The
detailed protocol is specified in the Supplementary Material. Briefly,
full-thickness punch biopsies were incubated with dispase solution
overnight at 41C. Epidermal sheets were carefully removed and
incubated in trypsin solution for 15 minutes at 371C. Trypsin was
inactivated by addition of 5 ml keratinocyte medium (DMEM low
glucose; HAM’s F12 adenine PenStrep plus HICE cocktail (hydro-
cortisone, insulin, cholera toxin, and EGF)). Cells were re-suspended
and seeded on plates with prepared feeder layer (consisting of
mitomycin C-treated adult fibroblasts). Medium was first replaced
after 2 days. At confluence (7–9 days), cells were split 1:2 or 1:3,
depending on confluence, and re-seeded on fresh feeder layer. After
a second passage 7 days later (splitting ratio 1:2), cells were
subjected to experiments. HaCaT keratinocytes were cultured in
RPMI 1640-containing GLUTAMAXTM-I (substituted on a molar
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Error bars indicate SD for all genes exceeding the threshold. Open symbols denote genes listed in Table 5. (b) Left, quantitative PCR showing gene
expression relative to hypoxanthine ribosyltransferase in primary keratinocytes from four donors stimulated with L-165041 for 48 hours. Right, mean7SD
of the changes for all individuals. *Po0.01; **Po0.001. (c) Western blot analysis: left, primary keratinocytes were stimulated as in panel (b), whole-cell
lysates separated by SDS-PAGE and blots probed with anti-HB-EGF. PonceauS staining is shown as a loading control. Right, primary keratinocytes were infected
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equivalent basis for L-glutamine), 100 U/ml Pen/Strep (Invitrogen-
Gibco, Karlsruhe, Germany), 10% fetal calf serum, and 0.4 mM calcium.
Synthetic ligand stimulation
Cells were seeded 5 105 cells/58 cm2 dish and incubated overnight
at 371C in a humidified atmosphere of 5% CO2. The selective PPARd
agonists L-165041 and GW-501516 (Calbiochem, Darmstadt,
Germany) were diluted and aliquoted in DMSO under N2 atmo-
sphere. Cells were stimulated with 1mM (L-165041) or 5mM (GW-
501516) for the time span specified in Results. Medium with fresh
ligand was added every 24 hours. Control cells received identical
volume of vehicle (0.05% v/v final DMSO).
Western blotting
Nuclear and cytoplasmic protein fractions were prepared using NE-
PER reagents (Pierce, Rockford, IL, no. 78833). For HB-EGF blots,
whole cell extracts were prepared with buffer containing CHAPS
exactly as described in Klose (1999). Protein extracts were aliquoted,
shock-frozen in liquid N2 and stored at 801C. Protein concentra-
tions were determined using BCA Protein Assay kit (Pierce, no.
23225). Twenty micrograms of protein extract was loaded per lane,
separated on 7.5% acrylamide-SDS gels, and blotted onto cellulose-
nitrate membranes (Whatman Schleicher & Schell, Dassel,
Germany, no. 10 402 594). Blots were blocked for 30 minutes with
4% non-fat milk in Tris-buffered saline with 0.05% Tween 20, and
subsequently incubated with primary and secondary antibodies in
4% non-fat milk/Tris-buffered saline with 0.05% Tween 20 as
follows. PPARd: rabbit anti-human PPARd polyclonal purified IgG
(Cayman Chemical Europe, Tallinn, Estonia, no. 101720; antigenic
peptide corresponds to aa 39-54 (SSSYTDLSRSSSPPSL)), diluted at
1:300 overnight at 41C; p65/RelA: (Santa Cruz Biotechnology, Santa
Cruz Biotech, CA, no. sc-109G) 1:1,000, overnight at 41C. HB-EGF:
(R&D Systems, Minneapolis, MN, AF-259-NA) 1:500, overnight
at 41C. Secondary antibodies were anti-rabbit-HRP (Amersham
Biosciences, Buckinghamshire, England, no. NA934) at 1:2,000,
anti-goat-HRP (Santa Cruz Biotechnology, no. SC-2922) 1:6,000.
Incubation with appropriate secondary antibody was carried for
1 hour at room temperature. Blots were developed with ECL Plus
Western Blotting Detection system (Amersham Biosciences, no.
RPN2 132).
RT-PCR
RNA extraction was performed using the NucleoSpin II extraction kit
(Machery-Nagel, Du¨ren, Germany, no. 740 955). All reagents used
for cDNA synthesis (SuperScript II Reverse Transcriptase, dNTP,
RnaseOut, Oligo(dT)12–18, dithiothreitol) were purchased from
Invitrogen-Gibco (Karlsruhe, Germany). GoTaq DNA Polymerase
(Promega, Mannheim, Germany, no. M3001) was used at 1 U/25ml
for amplification. The annealing temperature for all PCR reactions
was 551C except for PPARd (541C). Primer sets, number of cycles,
and amplicon lengths are detailed in the Supplementary Methods.
For quantitative real-time PCR, cDNA synthesis was performed
using Moloney Murine Leukemia Virus Reverse Transcriptase
(MMLV-RT). Amplification was performed in a TaqMan SDS7700,
using Assay-on-Demand kits (ABI) for hypoxanthine ribosyltransfer-
ase (Hs99999909_m1); CIDE-A (Hs00154455_m1), HB-EGF
(Hs00181813_m1), and PPARd (Hs00602622_m1) according to the
manufacturer’s instructions. Reactions were performed in triplicate
and expression levels normalized to hypoxanthine ribosyltransferase.
PPARd target gene identification
Primary keratinocyte culture, stimulation with L-165041, and RNA
preparation was performed as detailed above. Samples were labeled
either with Cy3 or Cy5, hybridized to Piquor SkinPatho microarrays
(Memorec, Cologne, Germany), and scanned by the Charite´
in-house microarray service facility. Dye swab experiments were
performed to rule out uneven green/red intensities. Data with at
least twice background intensity and %CV of less than 30% between
Table 5. Genes induced by PPARd activation in keratinocytes1
Gene ID Name FC P-value2 FC in vivo3
ABCC3 Multispecific organic anion transporter 2 1.870.1 o0.001 2.4
ACADVL Acyl-CoA dehydrogenase 2.870.4 o0.001 NS
AKR1B1 Aldose reductase 1.970.2 o0.001 NS
ATP12A K-transporting ATPase (non-gastric) 2.370.4 0.001 NT
BG1 Very long-chain acyl-CoA synthase 4.670.6 0.001 NT
CAT Catalase 2.570.9 0.008 NS
ECHB 3-ketoacyl CoA thiolase 2.070.5 0.012 NT
HB-EGF Heparin-binding EGF-like growth factor 1.970.1 0.009 3.64
KRT75 Cytokeratin type II (K6HF) 1.970.5 o0.001 NS
OACT5 O-acyltransferase domain containing 5 2.070.1 0.002 NS
PPARd, peroxisome proliferator-activated receptord.
1Epidermal keratinocytes were stimulated with the PPARd-specific ligand L-165041 or vehicle (DMSO) for 48 hours and gene expression profiling performed
using PIQUOR skin-patho microarrays as detailed in Materials and Methods. Data shown represent mean7SD of fold changes (L-165041 vs 0.1 % DMSO)
for cells from four independent donors.
2As calculated by a two-sided paired student’s t-test.
3Upregulation in lesional versus non-lesional psoriatic skin, as determined by microarray-based expression profiling (see Materials and Methods, complete
data set in Supplementary Methods ‘‘Charite´ all transcripts’’). NS, non-significant (P40.05), NT, transcript not present or not detected on U95A microrray.
4P=0.0026 for ABCC3; HB-EGF is not included in Table 3 because of the formally non-significant P-value (0.08, cf Supplementary Methods ‘‘all transcripts’’).
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the four replicas on each array were further analyzed as detailed
in Table 5.
Lentiviral transfer vectors
pLL3.7 [14] was a kind gift of Luk van Parijs. Short hairpin RNAi
sequence for PPARd : (50-tGTCGTACGATCCGCATGAAttcaagagaT
TCATG-CGGATCGTACGACttttttc) or b-catenin: (50-tGCTGAAAC
ATGCAGTTGTAttcaagaga-TACAACTGCATGTTTCAGCttttttc; target
sequence underlined) were synthesized in both strands, annealed,
and cloned immediately downstream of the U6 promoter using
HpaI/XhoI restriction sites. Parent plasmid served as control. An
alternative shRNAi sequence for PPARd (CCACTACGGTGTT
CATGC) was synthesized analogously with MluI and ClaI restriction
sites and cloned between under the control of H1 promoter of
pLVTH (Szulc et al., 2006), which was kindly provided by Didier
Trono, as well as pPAX2 and pMD2.G for second generation
packaging. Production of VSV-G pseudotyped replication-deficient
lentivirus was carried out according to Mitta et al. (2005). Lentivirus
infection was performed at a multiplicity of infection (MOI) of three
for 12 hours at 371C.
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